Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

trialsTrialRecruiting

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

A phase 1/2 trial of Amivantamab, Pembrolizumab and Carboplatin in head and neck squamous cell carcinoma, run by Janssen Research & Development, LLC, now recruiting.

Also called: OrigAMI-4

Overview Connected6

Overview

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer is a phase 1/2 interventional study registered as NCT06385080 by Janssen Research & Development, LLC, with 287 participants planned, started 2024-04-22 and due to reach its primary completion in 2032-12-27. Interventions recorded: Amivantamab, Pembrolizumab, Paclitaxel and Carboplatin.

Setting

A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase

Phase 1/2

Sponsor

Janssen Research & Development, LLC

Registry

Started

2024-04-22

Enrolled

287 enrolled

Connected

Similar pages

Trial
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Trial
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Trial
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Trial
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Trial
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Trial
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Trial
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Trial
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.

cancers

Head and neck squamous cell carcinoma

technologies

Bispecific antibodies

drugs

ApprovedBispecific antibody (EGFR×MET)

Amivantamab · Rybrevant

ApprovedCytotoxic chemotherapy (platinum)

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

companies

Johnson & Johnson

Evidence strength25/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
287 enrolled+12
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT06385080

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Head and neck squamous cell carcinoma

Technologies

Bispecific antibodies

Products

Amivantamab
Pembrolizumab
Carboplatin

Companies

Johnson & Johnson

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06385080/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06385080.

WebMCP tools registered on this page: onco_search, onco_get_entity.